Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Update

by · The Markets Daily

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Get Free Report) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 8,238 shares, a decline of 88.3% from the August 15th total of 70,257 shares. Currently, 3.0% of the shares of the company are sold short. Based on an average daily volume of 121,374 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On Scinai Immunotherapeutics

A hedge fund recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC raised its stake in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Free Report) by 146.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,630 shares of the company’s stock after purchasing an additional 17,031 shares during the period. Citadel Advisors LLC owned 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent quarter. 58.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Get Our Latest Research Report on SCNI

Scinai Immunotherapeutics Stock Down 2.3%

Shares of NASDAQ SCNI traded down $0.04 during midday trading on Thursday, hitting $1.67. 44,194 shares of the company’s stock were exchanged, compared to its average volume of 174,421. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.35 and a current ratio of 1.56. Scinai Immunotherapeutics has a 12 month low of $1.60 and a 12 month high of $16.40. The company’s 50 day moving average price is $2.49 and its 200 day moving average price is $4.46.

About Scinai Immunotherapeutics

(Get Free Report)

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.

Further Reading